AI assistant
BridgeBio Pharma, Inc. — Director's Dealing 2021
Aug 7, 2021
30604_dirs_2021-08-06_17a5d57f-55f5-4208-83bb-70549bad0b5d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2021-08-04
Reporting Person: SCHELLER RICHARD H (Director, See Remarks)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-08-04 | Common Stock | M | 13777 | $17.00 | Acquired | 59637 | Direct |
| 2021-08-04 | Common Stock | S | 13777 | $53.2276 | Disposed | 45860 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-08-04 | Stock Option (Right to Buy) | $17.00 | M | 13777 | Disposed | 2029-06-26 | Common Stock (13777) | Direct |
Footnotes
F1: Represents the weighted average sale price of the shares sold from $52.839 to $53.68 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in this footnote.
F2: The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such date.